Form 4 for DGX Quest Diagnostics
Accepted 2025-08-01 00:00:00 ET · period of report 2025-07-30 · accession 0001022079-25-000195 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-08-01 | 2025-07-30 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M - OptEx | $102.77 | +8,269 | 15.9K | +109% | +$849.8K |
| DM | 2025-08-01 | 2025-07-30+ | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | S - Sale+OE | $167.95 | -10.5K | 10.7K | -50% | -$1.76M |
| DM | 2025-08-01 | 2025-07-30 | DGX | KUPPUSAMY KARTHIK | SVP, Clinical Solutions | M - OptEx | $102.77 | -8,269 | 0 | -100% | -$849.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-07-30 | M | A | 3,045 | $86.63 | 13,705 | D | — | — | |
| 2 | Common | Common Stock | 2025-07-30 | S | D | 3,045 | $167.40 | 10,660 | D | — | — | |
| 3 | Common | Common Stock | 2025-07-31 | S | D | 2,210 | $170.00 | 8,450 | D | — | — | |
| 4 | Common | Common Stock | 2025-07-30 | S | D | 5,224 | $167.40 | 10,660 | D | — | — | |
| 5 | Common | Common Stock | 2025-07-30 | M | A | 5,224 | $112.17 | 15,884 | D | — | — | |
| 6 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-07-30 | M | D | 3,045 | $86.63 | 0 | D | $86.63 · — to 2029-02-18 | 3,045 Common Stock | (F3) The options vested in three annual installments beginning with the first on February 18, 2020, the second on February 18, 2021 and the final on February 18, 2022. |
| 7 | Derivative | Non-Qualifed Stock Option (right to buy) | 2025-07-30 | M | D | 5,224 | $112.17 | 0 | D | $112.17 · — to 2030-02-18 | 5,224 Common Stock | (F4) The options vested in three annual installments beginning with the first on February 18, 2021, the second on February 18, 2022 and the final on February 18, 2023. |